Paper Details

  1. Home
  2. Paper Details

Safety and tolerability of 13-valent pneumococcal conjugate vaccine in the elderly.

Author: AlbaneseErika, BarberisIlaria, BreganteAlessandro, CaccianiRoberto, CremonesiIlaria, DurandoPaolo, IudiciRocco, La MarcaDiego, MarensiLorenzo, MartiniMariano, OrsiAndrea, PaganinoChiara, PedanoLeonardo, PetrucciAmadio Franco, RosselliRoberto, SantoliniMaria, SbisàValentina, Study GroupThe Ligurian Pneumococcal, TrucchiCecilia, TurelloValter, ZacconiMonica

Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Observational StudyResearch that observes and collects data on participants' behavior and outcomes in their natural state, without intervention.

Overview

The European Medical Agency and the Food and Drug Administration have authorized the use of 13-valent pneumococcal conjugate vaccine (PCV13) in adults aged ≥50 years for the prevention of invasive pneumococcal diseases and community acquired pneumonia. The Liguria Region, in Italy, implemented an active and free of charge immunization strategy with PCV13 among adults with specific risk conditions and the elderly aged ≥70 years.
Paper Details　
Original Abstract of the Article :
In September 2011 the European Medical Agency authorized the use of 13-valent pneumococcal conjugate vaccine (PCV13) in adults aged ≥50 years. The same occurred in the US in December 2011 when the Food and Drug Administration approved the use of PCV13 in the same target age-group with indication for...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514209/

データ提供：米国国立医学図書館（NLM）

Protecting Seniors from Pneumococcal Disease

The elderly population is particularly vulnerable to pneumococcal disease, a serious infection caused by bacteria. This research focuses on the safety and tolerability of 13-valent pneumococcal conjugate vaccine (PCV13) in adults aged 50 years and older. The researchers highlight the approval of PCV13 for use in this age group in both Europe and the United States, emphasizing its potential to prevent invasive pneumococcal diseases and community-acquired pneumonia in seniors. They also describe the implementation of a free immunization strategy with PCV13 among adults at risk and the elderly aged 70 years and older in the Liguria Region of Italy, demonstrating the importance of widespread vaccination programs to protect vulnerable populations.

The Importance of Vaccination in Protecting Seniors

Vaccination is a crucial tool for preventing infectious diseases, especially in vulnerable populations like the elderly. This research provides evidence for the safety and tolerability of PCV13 in seniors, encouraging the widespread adoption of vaccination programs to protect this age group from pneumococcal disease. The implementation of a free vaccination strategy in the Liguria Region of Italy serves as a model for other regions to follow, emphasizing the importance of accessible and affordable vaccination services for all. The study's findings underscore the critical role of vaccination in protecting the health and well-being of seniors.

Living Longer and Healthier Lives

Vaccinations are a powerful tool for promoting public health and preventing infectious diseases. The research on PCV13's safety and tolerability in seniors is a significant step towards protecting this age group from pneumococcal disease. By promoting widespread vaccination, we can help seniors live longer, healthier, and more fulfilling lives. The findings of this research serve as a reminder of the importance of investing in public health initiatives and prioritizing the well-being of all individuals, especially those who are most vulnerable.

Dr.Camel's Conclusion

Just like a camel adapts to the arid desert environment, vaccination helps individuals build resilience against infectious diseases. This research emphasizes the importance of protecting seniors, who are often more susceptible to infections, through widespread vaccination programs. PCV13 offers a safe and effective way to prevent pneumococcal disease in this age group, contributing to a healthier and more fulfilling life for our elders.

Date :
  1. Date Completed 2015-10-26
  2. Date Revised 2018-11-13
Further Info :

Pubmed ID

25483531

DOI: Digital Object Identifier

PMC4514209

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.